Profusa Inc(PFSA) 가격

Profusa, Inc. engages in the biofeedback for chronic disease management and healthy living services. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-12-20. The firm is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.